NASDAQ:HGEN Humanigen (HGEN) Stock Price, News & Analysis → Trending Stocks Sent To You In Real Time (From Huge Alerts) (Ad) Free HGEN Stock Alerts Add Compare Share Share Today's Range N/A50-Day Range N/A52-Week Range N/AVolume3,300 shsAverage Volume3.26 million shsMarket Capitalization$36,000.00P/E RatioN/ADividend YieldN/APrice Target$0.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsSocial Media Get Humanigen alerts: Email Address Ad DTICBOE shift unlocks new weekend income strategyYou might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange. You're probably wondering, “Okay… But how does that affect me?” This perk now allows everyday traders like yourself to target extra income over the weekend. Check out this training for the full story! About Humanigen Stock (NASDAQ:HGEN)Humanigen, Inc., a clinical-stage biopharmaceutical company, focuses on preventing and treating an immune hyper-response. The company is developing lenzilumab, an antibody that binds to and neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF), to treat cytokine storm associated with COVID-19 for which it has completed a Phase 3 study and is the focus of a Phase 2/3 study sponsored by the NIH. It is also developing lenzilumab, which is associated with CD19-targeted CAR-T cell therapies, as well as exploring the effectiveness of lenzilumab in other inflammatory conditions, such as acute Graft versus Host Disease in patients undergoing allogeneic hematopoietic stem cell transplantation and in eosinophilic asthma, and rheumatoid arthritis. In addition, the company focuses on studying lenzilumab for patients with chronic myelomonocytic leukemia exhibiting RAS pathway mutations. Its pipeline also includes two other Humaneered monoclonal antibodies, ifabotuzumab, which binds to EphA3, and HGEN005, which targets EMR1, as well as treats a range of eosinophilic diseases, including eosinophilic leukemia as an optimized naked antibody and as the backbone for a novel CAR-T construct. Humanigen, Inc. was incorporated in 2000 and is headquartered in Short Hills, New Jersey. On January 3, 2024, Humanigen, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.Read More Ad DTICBOE shift unlocks new weekend income strategyYou might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange. You're probably wondering, “Okay… But how does that affect me?” This perk now allows everyday traders like yourself to target extra income over the weekend. Check out this training for the full story! HGEN Stock News HeadlinesMarch 24, 2024 | finance.yahoo.comHumanigen Inc (0KB2.BE)February 6, 2024 | morningstar.comHumanigen Inc HGENQMarch 28, 2024 | MarketBeat (Ad)Your $200 account credit is about to expireUpdate to MarketBeat All Access and Save $300 on Your Annual SubscriptionJanuary 25, 2024 | markets.businessinsider.comLevi & Korsinsky, LLP Notifies Shareholders of Humanigen, Inc. (HGEN) an Upcoming Claims Deadline in a Class Action SettlementJanuary 17, 2024 | wsj.comFirm Retention Summary: HumanigenJanuary 5, 2024 | msn.comHumanigen Downfall: FDA Rejection For COVID-19 Drug Triggers Financial Crisis, BankruptcyJanuary 4, 2024 | news.yahoo.comCOVID-19 treatment developer Humanigen files for Chapter 11 bankruptcyJanuary 4, 2024 | wsj.comCovid-19 Treatment Developer Humanigen Files for BankruptcyMarch 28, 2024 | DTI (Ad)the most reliable asset on earth is making a comebackGlobal tensions have been pushing the price of gold to all time highs… Just recently, gold peaked at a record $2,000 (and is now closer to $2,200). And there’s something else critical at play right now in the world’s largest asset. Because of these critical factors, a lot of massive investment institutions are now pumping more money into gold. And as we speak, some are even calling for a massive rally in the precious metal.January 4, 2024 | msn.comCOVID pick Humanigen files for bankruptcyDecember 9, 2023 | finanznachrichten.deAktueller Chart HUMANIGEN AktieOctober 13, 2023 | uk.finance.yahoo.comHumanigen, Inc. (HGEN) stock historical prices & data – Yahoo FinanceAugust 11, 2023 | uk.finance.yahoo.comHumanigen, Inc. (HGEN) stock price, news, quote & history – Yahoo FinanceAugust 7, 2023 | finance.yahoo.comHumanigen Announces First Participant Dosed in RATinG Trial of Lenzilumab for Early Treatment of Acute Graft Versus Host Disease Following Allogeneic Stem Cell TransplantationJuly 30, 2023 | proactiveinvestors.comHumanigen stock removed from S&P Total Market Index as firm faces...July 28, 2023 | proactiveinvestors.comHumanigen stock removed from S&P Total Market Index as firm faces bankruptcyJuly 25, 2023 | marketwatch.comHumanigen Shares Plunge 73% as Business Combination Fails, Going Concern Issues RaisedJuly 25, 2023 | markets.businessinsider.comWhy Is Humanigen (HGEN) Stock Down 72% Today?July 25, 2023 | msn.comHumanigen (NASDAQ:HGEN) Nosedives with Bankruptcy Looming LargeJuly 25, 2023 | seekingalpha.comHumanigen to weigh bankruptcy as shares delist from NasdaqApril 17, 2023 | nasdaq.comHumanigen (HGEN) Surges on Lenzilumab Study Data for LeukemiaApril 14, 2023 | finance.yahoo.comHumanigen - Lenzilumab Being Studied as a Potential First Treatment in Thirty Years with a Novel Mechanism of Action for Chronic Myelomonocytic Leukemia (CMML), an Orphan Form of LeukemiaDecember 20, 2022 | finance.yahoo.comHumanigen, Inc. (HGEN) Stock Historical Prices & Data - Yahoo FinanceNovember 14, 2022 | finance.yahoo.comHumanigen Reports Third Quarter 2022 Financial ResultsNovember 10, 2022 | finance.yahoo.comHumanigen Announces Participation and Presentation at Jefferies London Healthcare ConferenceOctober 31, 2022 | finance.yahoo.comHumanigen Announces Retention of SC&H Capital as Financial AdvisorOctober 19, 2022 | stockhouse.com2022-10-19 | NDAQ:HGEN | Press Release | Humanigen Inc. - StockhouseSee More Headlines Receive HGEN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Humanigen and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/12/2021Today3/27/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolNASDAQ:HGEN CUSIPN/A CIK1293310 Webwww.humanigen.com Phone650-243-3100FaxN/AEmployees6Year FoundedN/APrice Target and Rating Average Stock Price Target$0.50 High Stock Price Target$0.50 Low Stock Price Target$0.50 Potential Upside/Downside+166,566.7%Consensus RatingSell Rating Score (0-4)1.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$1.70 million Price / Sales0.02 Cash FlowN/A Price / Cash FlowN/A Book Value($0.45) per share Price / Book0.00Miscellaneous Outstanding Shares119,080,000Free Float93,240,000Market Cap$35,724.00 OptionableNo Data Beta-1.04 10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free Report Key ExecutivesDr. Cameron Durrant M.D. (Age 64)MBA, Chairman, CEO & Acting CFO Comp: $640kDr. Dale Chappell M.B.A. (Age 54)M.D., MBA, Chief Scientific Officer & Director Comp: $410kKey CompetitorsCalithera BiosciencesNASDAQ:CALAIgnyte AcquisitionNASDAQ:IGNYStatera BiopharmaNASDAQ:STABBruush Oral CareNASDAQ:BRSHNovanNASDAQ:NOVNView All Competitors HGEN Stock Analysis - Frequently Asked Questions Should I buy or sell Humanigen stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Humanigen in the last twelve months. There are currently 1 sell rating for the stock. The consensus among Wall Street research analysts is that investors should "sell" HGEN shares. View HGEN analyst ratings or view top-rated stocks. What is Humanigen's stock price target for 2024? 1 brokerages have issued 12 month price targets for Humanigen's shares. Their HGEN share price targets range from $0.50 to $0.50. On average, they predict the company's stock price to reach $0.50 in the next twelve months. This suggests a possible upside of 166,566.7% from the stock's current price. View analysts price targets for HGEN or view top-rated stocks among Wall Street analysts. How have HGEN shares performed in 2024? Humanigen's stock was trading at $0.0012 at the beginning of the year. Since then, HGEN stock has decreased by 75.0% and is now trading at $0.0003. View the best growth stocks for 2024 here. How were Humanigen's earnings last quarter? Humanigen, Inc. (NASDAQ:HGEN) released its quarterly earnings results on Friday, November, 12th. The company reported ($1.12) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.98) by $0.14. The firm earned $1.04 million during the quarter, compared to analysts' expectations of $0.40 million. When did Humanigen's stock split? Humanigen shares reverse split on Monday, September 14th 2020. The 1-5 reverse split was announced on Friday, September 4th 2020. The number of shares owned by shareholders was adjusted after the closing bell on Friday, September 11th 2020. An investor that had 100 shares of stock prior to the reverse split would have 20 shares after the split. How do I buy shares of Humanigen? Shares of HGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:HGEN) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisorySHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceBuy this small stock before coming AI Tidal WaveChaikin AnalyticsThe 3rd Revolution in WarfareWeiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Humanigen, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.